Survival Analysis of Irish Amyotrophic Lateral Sclerosis Patients Diagnosed from 1995–2010

Introduction The Irish ALS register is a valuable resource for examining survival factors in Irish ALS patients. Cox regression has become the default tool for survival analysis, but recently new classes of flexible parametric survival analysis tools known as Royston-Parmar models have become available. Methods We employed Cox proportional hazards and Royston-Parmar flexible parametric modeling to examine factors affecting survival in Irish ALS patients. We further examined the effect of choice of timescale on Cox models and the proportional hazards assumption, and extended both Cox and Royston-Parmar models with time varying components. Results On comparison of models we chose a Royston-Parmar proportional hazards model without time varying covariates as the best fit. Using this model we confirmed the association of known survival markers in ALS including age at diagnosis (Hazard Ratio (HR) 1.34 per 10 year increase; 95% CI 1.26–1.42), diagnostic delay (HR 0.96 per 12 weeks delay; 95% CI 0.94–0.97), Definite ALS (HR 1.47 95% CI 1.17–1.84), bulbar onset disease (HR 1.58 95% CI 1.33–1.87), riluzole use (HR 0.72 95% CI 0.61–0.85) and attendance at an ALS clinic (HR 0.74 95% CI 0.64–0.86). Discussion Our analysis explored the strengths and weaknesses of Cox proportional hazard and Royston-Parmar flexible parametric methods. By including time varying components we were able to gain deeper understanding of the dataset. Variation in survival between time periods appears to be due to missing data in the first time period. The use of age as timescale to account for confounding by age resolved breaches of the proportional hazards assumption, but in doing so may have obscured deficiencies in the data. Our study demonstrates the need to test for, and fully explore, breaches of the Cox proportional hazards assumption. Royston-Parmar flexible parametric modeling proved a powerful method for achieving this.

[1]  Mitchell H. Katz,et al.  Multivariable analysis : a practical guide for clinicians and public health researchers , 2011 .

[2]  O. Hardiman,et al.  Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia , 2011, Neurology.

[3]  Paul C. Lambert,et al.  Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model , 2011 .

[4]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[5]  A. Al-Chalabi,et al.  Early symptom progression rate is related to ALS outcome: a prospective population-based study. , 2002, Neurology.

[6]  J. Benichou,et al.  Choice of time‐scale in Cox's model analysis of epidemiologic cohort data: a simulation study , 2004, Statistics in medicine.

[7]  O. Hardiman,et al.  Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000 , 2003, Journal of neurology, neurosurgery, and psychiatry.

[8]  O. Hardiman,et al.  Incidence and prevalence of ALS in Ireland, 1995–1997 , 1999, Neurology.

[9]  Matthew C. Kiernan,et al.  Clinical diagnosis and management of amyotrophic lateral sclerosis , 2011, Nature Reviews Neurology.

[10]  Fei Gao,et al.  Age at diagnosis and the choice of survival analysis methods in cancer epidemiology. , 2003, Journal of clinical epidemiology.

[11]  P. Royston,et al.  Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.

[12]  E. Beghi,et al.  Predictors of long survival in amyotrophic lateral sclerosis: A population-based study , 2008, Journal of the Neurological Sciences.

[13]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[14]  O. Hardiman,et al.  Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. , 2000, Archives of neurology.

[15]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[16]  A. Arroliga,et al.  Objective measures of the efficacy of noninvasive positive‐pressure ventilation in amyotrophic lateral sclerosis , 2001, Muscle & nerve.

[17]  E L Korn,et al.  Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. , 1997, American journal of epidemiology.

[18]  Tx Station Stata Statistical Software: Release 7. , 2001 .

[19]  P. Shaw,et al.  Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial , 2006, The Lancet Neurology.

[20]  Yulia V. Marchenko,et al.  An Introduction to Survival Analysis Using Stata, Third Edition , 2010 .

[21]  G W Sun,et al.  Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. , 1996, Journal of clinical epidemiology.

[22]  D.,et al.  Regression Models and Life-Tables , 2022 .

[23]  P. Lambert STPM2: Stata module to estimate flexible parametric survival models , 2010 .

[24]  V. Meininger,et al.  Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.